Polyphor has closed an IPO to continue developing a new class of antibiotics against pneumonia, as well as treatments for cystic fibrosis and breast cancer. Polyphor, based in Switzerland, has raised a substantial IPO of CHF 165M (€138M) on the SIX ...
This awesome article Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)
Original Article: Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance